Open archive
Clear filters
Showing 1-7 of 7 published briefings.
Company archive
Green Cross Health (GXH) briefings
Read that company's published results in release order, newest first.
Green Cross Health (GXH)FY26Released 29 May 2026
Medical services-led NPAT growth of 27.5% on 4.2% revenue lift
The earnings step-up was concentrated in the smaller Medical services segment while operating cash flow grew only 3.7% and free cash flow fell.
Published 29 May 2026
Read briefingGreen Cross Health (GXH)HY26Released 28 November 2025
NPAT grew 28.6% but pre-lease FCF fell to NZ$15.6m, a 3-year low
Working capital absorption and a near-tripling of capex weakened cash conversion even as reported earnings grew above the historical range.
Published 22 April 2026
Read briefingGreen Cross Health (GXH)HY25Released 28 November 2024
FCF jumped to $23.1m on debtor release while ROE slipped to 3.3%
NPAT was flat at $5.6m and returns sat below the historical baseline as a $4.9m receivables drawdown drove most of the cash uplift.
Published 22 April 2026
Read briefingGreen Cross Health (GXH)FY24Released 30 May 2024
Net cash flipped to $11.5m net debt as continuing PBT fell 17.3%
Operating cash held flat but reserves fell $34.8m and borrowings rose 48.5%, with the final dividend cut 42.9% to 2.0 cents.
Published 22 April 2026
Read briefingGreen Cross Health (GXH)HY24Released 29 November 2023
Pharmacy EBIT fell 25% as COVID tail faded; net cash flipped to net debt
The 29.5% headline revenue drop reflects the Community Health divestment, but continuing operations show eroding margins and a balance sheet that no
Published 22 April 2026
Read briefingGreen Cross Health (GXH)FY23Released 30 May 2023
NPAT up 83.7% on $30.3m disposal gain as continuing PBT fell 43.5%
The discontinued operation supplied two-thirds of reported NPAT while operating cash flow fell 30.3% and continuing EBIT dropped 29%.
Published 22 April 2026
Read briefingGreen Cross Health (GXH)HY23Released 25 November 2022
PBT up 20.3% as Medical and Community offset pharmacy weakness
The dominant pharmacy segment lost revenue share and earnings while a 30.3% effective tax rate clipped NPAT growth to 17.5%.
Published 22 April 2026
Read briefingGet reporting-season briefings
Get full NZX result briefings by email as new coverage is published.